A pharmaceutical composition for interventional treatment of uterine fibroids and its preparation method

Abstract

The invention relates to a uterine myoma interventional treatment medicine composition and a preparation method thereof. The medicine composition comprises prostaglandin or an analogue thereof, an optional anti-tumor drug and a gel carrier. As the prostaglandin or the analogue thereof is added into an embolic agent for treating uterine myoma by intervention, the viability of uterine myoma cells under ischemic and anaerobic conditions can be effectively improved in the interventional treatment process, necrosis of the uterine myoma cells is accelerated, uterine myoma atrophy and necrosis time is effectively shortened, adverse effects such as inflammatory fever and pain in the treatment process are relieved, contraction of uterine smooth muscles can be promoted, bleeding caused by uterine myoma detachment is decreased, and the occurrence probability of secondary infection possibly caused by interventional treatment of the uterine myoma can be reduced.

Description

technical field [0001] The invention belongs to the field of medicines, and in particular relates to a pharmaceutical composition for interventional treatment of uterine fibroids and a preparation method thereof. Background technique [0002] Uterine fibroids, also known as uterine leiomyomas, are common benign tumors in gynecology. They mostly occur in women between the ages of 30 and 50. The incidence rate is as high as 20% to 40%. Most patients are asymptomatic, but some patients have symptoms Menstrual disorders, abdominal distension, abdominal pain, infertility, anemia, increased leucorrhea, irregular vaginal bleeding, frequent urination, urgency and other symptoms. Although uterine fibroids are benign tumors, they will seriously affect the quality of daily life of patients. Therefore, active treatment is still required. [0003] At present, interventional therapy is more and more widely used in the treatment of uterine fibroids. It injects embolic agents or pingyangmy...

AI Technical Summary

Problems solved by technology

[0004] CN102988274A discloses a drug slow-release vascular embolism gel for treating tumors, which is made by encapsulating the drug through a gel made of a pharmaceutical carrier, and can be used as an arterial embolization agent for uterine fibroids. The drug includes Methotrexate, fluorouracil, tegafur, nitrogen mustard, cyclophosphamide, cisplatin and other anti-tumor drugs, so that the anti-tumor effect of anti-tumor drugs can be further used in the interventional treatment of uterine fibroids, but due to the use of interventional methods During the treatment, the uterine fibroid cells are already in a state of ischemia and hypoxia, and the effect of further antitumor drugs is limited

Images